Dengue virus exploits autophagy vesicles and secretory pathways to promote transmission by human dendritic cells.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 17 07 2023
accepted: 19 04 2024
medline: 12 6 2024
pubmed: 12 6 2024
entrez: 12 6 2024
Statut: epublish

Résumé

Dengue virus (DENV), transmitted by infected mosquitoes, is a major public health concern, with approximately half the world's population at risk for infection. Recent decades have increasing incidence of dengue-associated disease alongside growing frequency of outbreaks. Although promising progress has been made in anti-DENV immunizations, post-infection treatment remains limited to non-specific supportive treatments. Development of antiviral therapeutics is thus required to limit DENV dissemination in humans and to help control the severity of outbreaks. Dendritic cells (DCs) are amongst the first cells to encounter DENV upon injection into the human skin mucosa, and thereafter promote systemic viral dissemination to additional human target cells. Autophagy is a vesicle trafficking pathway involving the formation of cytosolic autophagosomes, and recent reports have highlighted the extensive manipulation of autophagy by flaviviruses, including DENV, for viral replication. However, the temporal profiling and function of autophagy activity in DENV infection and transmission by human primary DCs remains poorly understood. Herein, we demonstrate that mechanisms of autophagosome formation and extracellular vesicle (EV) release have a pro-viral role in DC-mediated DENV transmission. We show that DENV exploits early-stage canonical autophagy to establish infection in primary human DCs. DENV replication enhanced autophagosome formation in primary human DCs, and intrinsically-heightened autophagosome biogenesis correlated with relatively higher rates of DC susceptibility to DENV. Furthermore, our data suggest that viral replication intermediates co-localize with autophagosomes, while productive DENV infection introduces a block at the late degradative stages of autophagy in infected DCs but not in uninfected bystander cells. Notably, we identify for the first time that approximately one-fourth of DC-derived CD9/CD81/CD63+ EVs co-express canonical autophagy marker LC3, and demonstrate that DC-derived EV populations are an alternative, cell-free mechanism by which DCs promote DENV transmission to additional target sites. Taken together, our study highlights intersections between autophagy and secretory pathways during viral infection, and puts forward autophagosome accumulation and viral RNA-laden EVs as host determinants of DC-mediated DENV infection in humans. Host-directed therapeutics targeting autophagy and exocytosis pathways thus have potential to enhance DC-driven resistance to DENV acquisition and thereby limit viral dissemination by initial human target cells following mosquito-to-human transmission of DENV.

Identifiants

pubmed: 38863700
doi: 10.3389/fimmu.2024.1260439
pmc: PMC11165123
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1260439

Informations de copyright

Copyright © 2024 Cloherty, Rader, Patel, Eisden, van Piggelen, Schreurs and Ribeiro.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Alexandra P M Cloherty (APM)

Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, Netherlands.

Anusca G Rader (AG)

Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, Netherlands.
Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, Netherlands.

Kharishma S Patel (KS)

Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, Netherlands.

Tracy-Jane T H D Eisden (TTHD)

Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, Netherlands.
Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.

Sterre van Piggelen (S)

Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, Netherlands.

Renée R C E Schreurs (RRCE)

Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, Netherlands.
Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, Netherlands.

Carla M S Ribeiro (CMS)

Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, Netherlands.
Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH